The Biden administration is taking steps to change how antibody treatments are distributed to the states, sparking intense backlash from leaders across the country who advocate for the life-saving treatments.
As reported by Fortune, “Hospitals and other care providers will no longer be able to directly order monoclonal antibody therapies from distributors, according to a Sept. 13 update posted on the Department of Health and Human Services website.”
“Instead, the U.S. government will determine what quantity of the drugs to ship to each state and territory based on Covid-19 case numbers and use of the treatments locally. State health departments will then determine how to distribute the antibody therapies to hospitals and other sites, according to the HHS update,” the outlet added.
“Federal health officials plan to allocate specific amounts to each state under the new approach, in an effort to more evenly distribute the 150,000 doses that the government makes available each week,” Politico reported. “The approach is likely to cut into shipments to GOP-led states in the Southeast that have made the pricey antibody drug a central part of their pandemic strategy, while simultaneously spurning mask mandates and other restrictions.”
Keep reading at The Daily Wire for more.